Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention

Climacteric

Volumn 15, Issue 5, 2012, Pages 411-418

  Pinkerton, J V ^a   Pickar, J H ^b   Racketa, J ^c   Mirkin, S ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c PFIZER INC   (United States)

Author keywords

bazedoxifene; conjugated estrogens; menopause; osteoporosis; Tissue selective estrogen complex; TSEC; vasomotor symptoms

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; PLACEBO; UNCLASSIFIED DRUG;

AMENORRHEA; BONE ATROPHY; BONE DENSITY; BREAST; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; HOT FLUSH; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; NONHUMAN; OVARY CYST; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP; VAGINA ATROPHY; VASOMOTOR DISORDER;

ADULT; AGED; ATROPHY; CLINICAL TRIALS, PHASE III AS TOPIC; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84866395340     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.696289     Document Type: Review

References (35)

1. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002; 57: 257-75
2. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006; 96: 1226-35 (Pubitemid 43967848)
3. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of va-somotor symptoms in middle-aged women: a longitudinal study. Menopause 2009; 16: 453-7
4. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008; 15: 661-6
5. Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J Pelvic Floor Dysfunct 2001; 12: 107-10 (Pubitemid 32451986)
6. Burger HG. The endocrinology of the menopause. Maturitas 1996; 23: 129-36 (Pubitemid 126351815)
7. Riggs BL, Khosla S, Melton LJ III. A unitary model for in-volutional osteoporosis: estrogen defi ciency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763-73 (Pubitemid 28224192)
8. National Osteoporosis Foundation. Fast facts on osteoporosis. http://www.nof.org/node/40 [serial online]; Accessed November 17, 2011
9. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-55
10. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-7
11. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without pro-gestins. J Natl Cancer Inst 1999; 91: 1131-7 (Pubitemid 29330551)
12. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the fi ndings of the Women's Health Initiative. Menopause 2005; 12: 399-404 (Pubitemid 41098652)
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33 (Pubitemid 34761611)
14. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008; 149: 6084-91
15. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009; 23: 75-85
16. Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profi ling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010; 118: 117-24
17. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009; 150: 1897-903
18. Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 2011; 49: 376-86
19. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Effi cacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92: 1045-52
20. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039-44
21. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of meno-pausal symptoms and effects on metabolic parameters and overall safety profi le. Fertil Steril 2009; 92: 1025-38
22. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018-24
23. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24
24. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in post-menopausal women. Maturitas 2009; 63: 329-35
25. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281-9
26. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010; 13: 132-40
27. Pinkerton JV, Pan K, Pickar J, Mirkin S. Effects of bazedoxifene/ conjugated estrogens (BZA/CE) on hot fl ushes in postmenopausal women: effect of timing of therapy initiation. Endocr Rev 2010; 31(3 Suppl 1): S1304
28. Mirkin S, Pan K, Chines AA. Effects of body mass index and years since menopause on the effi cacy of bazedoxifene/conjugated estrogens (BZA/CE) on vasomotor symptoms. Menopause 2010; 17: 1234-5
29. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE). Menopause 2010; 17: 1219
30. Pinkerton JV, Racketa J, Shi H, Chines AA, Mirkin S. Evaluation of secondary outcomes in postmenopausal women treated with bazedoxifene/conjugated estrogen by years since menopause. Climacteric 2011; 14(Suppl 1): 172 (Abstr)
31. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause 2010; 17: 1237-8
32. Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause 2010; 17: 1221-2
33. Pinkerton JA, Constantine GD, Komm BS, Yu H, Pickar JH. Breast effects of bazedoxifene/conjugated estrogens in a randomized, controlled trial of postmenopausal women. Poster presented at the 19th Annual Meeting of the North American Menopause Society, September 24-27, 2008, Lake Buena Vista, FL, USA
34. Harvey JA, Pinkerton JV, Baracat EC, Shi H, Mirkin S, Chines AA. Evaluation of changes in mammographic breast density associated with bazedoxifene/conjugated estrogens in postmeno-pausal women. Endocr Rev 2011; 32: 1-79
35. Gaspard UJ, Gottal JM, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995; 21: 171-8